Business
Danaher succeeds after cutting Covid-related revenue from growth reports
Danaher
The company’s fourth-quarter earnings beat expectations, but the stock fell early Tuesday. This is due to first-quarter guidance and a reassessment of its earnings report, according to analysts at RBC Capital Markets.
In the face of fluctuations in demand for Covid-19 related products,
Danaher
(ticker: DNR) has adjusted its definition of revenue growth to exclude those items, starting in the first quarter of 2023, according to the company’s earnings report. On that basis, the medical company forecasts average single-digit revenue growth for the first quarter and high single-digit growth for the whole of 2023.